Table 1.
Study selection criteria to identify trials for the SLR.
| Criteria | Description |
|---|---|
| Population | Stage III melanoma |
| Sub-groups of interest: • BRAF mutation status | |
| Interventions | Pembrolizumab |
| Interferon (IFN)-α2a | |
| IFN-α2b | |
| Pegylated IFN-α2b | |
| Nivolumab | |
| Ipilimumab | |
| Dabrafenib in combination with trametinib | |
| Temozolomide in combination with cisplatin | |
| Vemurafenib | |
| Comparisons | Placebo or best supportive care (BSC) |
| Any intervention of interest as monotherapy or in combination | |
| Any treatment that facilitates an indirect treatment comparison | |
| Outcomes | Recurrence-free (or relapse-free) survival (RFS) |
| Study design | Randomized controlled trials |
| Systematic literature reviews | |
| Meta-analyses | |
| Other | English language |
| No time restriction |